Company Overview and News
Monthly paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
MGRUF FFN NAF.UN CRIUF MHIVF ATGFF RNW SOT.UN EFRTF AHOTF DR.DB.A DVVDF TRSWF ARESF DR CNDCF KWH.UN BK MFCSF FNCSF ALA
It's your September 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays <$200M are not listed.
CRLFF CRIUF ORC MHIVF GLADO ATGFF AGNC TRSWF KWH.UN PSEC SCQ PBB MGRUF SCA CJ GOOD OXLCO OXLCN SCM GOODM GLAD SOT.UN RNW GOODN ECC ECCZ AHOTF ECCY GOODO GOODP SRRTF ARESF CGIFF PZRIF ?NHF? OXLC ECCB ARR ECCA SUNS GNL NHF ALA SRT.UN PZA
Here's your August 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays are not listed.
MGRUF SCA CJ CRLFF CRIUF ORC MHIVF RA OXLCO OXLCN SCM GLADO ATGFF GLAD SOT.UN RNW ECC ECCZ AGNC AHOTF ECCY TRSWF SRRTF KWH.UN CGIFF ?NHF? PSEC OXLC ECCB ARR SCQ ECCA SUNS GNL NHF PBB ALA OPP SRT.UN
Over the past few years, Artis REIT has reduced its exposure to the real estate market in Alberta.
It has an attractive dividend yield of 7.1% and development projects that should improve its net operating income over time.
Allied Properties REIT (OTCPK:APYRF) (TSX:AP.UN) owns a portfolio of high-quality urban office properties in Canada. The REIT has a healthy development pipeline that should significantly expand its portfolio. It also has an excellent track record of dividend growth since its inception. However, its share price is currently trading at a premium. Investors are encouraged to check other REITs before making their investment decision.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET